Published on:

Similac and Enfamil Class Action Lawsuit

Clinical studies have conclusively shown that baby formula made from cow’s milk, such as Similac and Enfamil, is dangerous to premature infants because they significantly increase the risk of a dangerous infection called necrotizing enterocolitis (NEC). Over the last year, a growing number of product liability lawsuits have been filed against the manufacturers of Similac and Enfamil by parents of premature babies who developed NEC. These NEC formula lawsuits allege that the formula makers knew their products were dangerous to preemies and deliberately failed to warn about the risk of NEC.

In this post, we will look at the current status of the infant formula NEC lawsuits against the manufacturers of Enfamil and Similac. We will look at where these NEC formula lawsuits are being filed, how many are currently pending, who the major players are on both sides (plaintiff and defendant), and other details.


  • June 2022: The new NEC formula MDL is already growing rapidly. 26 new cases were added in the first two weeks to bring the total up to 78 pending cases (as of June 6). Meanwhile, the judge in the MDL issued an order naming her selections for the attorneys that will represent the larger group of plaintiffs as Lead Counsel and Liasion Counsel. These lawyers will now make many of the strategic decisions on behalf of all the plaintiffs in the case and will handle the bellwether test trials. 
  • May 2022: The new baby formula NEC class-action MDL in N.D. Ill. is now up and running (In re: Abbott Laboratories, et al., Preterm Infant Nutrition Prod. Liab. Lit.– MDL No. 3026). A total of 52 NEC lawsuits have been consolidated into the new MDL and are currently pending, but this number will most likely triple over the next month as more cases are transferred in from across the federal districts. 
  • April 2022: The JPML has agreed to centralize the growing number of infant formula NEC lawsuits into a new class-action MDL. The new MDL has been assigned to Judge Rebecca Pallmeyer in the Northern District of Illinois. N.D. Illinois was an obvious choice for the venue because both of the primary defendants (Abbott and Mead Johnson) are based in the Chicago area.
  • March 2022:  Abbott is still reeling from the Similac recall last month that has already led to a class action lawsuit. 
  • February 2022: Abbott and Mead capitulated to an MDL-type class action in Illinois state court.  Lawyers from other jurisdictions are filing NEC lawsuits in Illinois state court.
  • January 2022: Last month, lawyers for a group of 30 plaintiffs with NEC formula cases pending in Illinois state courts filed a petition asking the Supreme Court of Illinois to consolidate their cases into a single action (the Illinois equivalent of an MDL). Illinois has become the focal point for the NEC formula litigation because both Abbott & Mead Johnson are headquartered in the Chicago area. Abbott and Mead were recently granted an extension of time to respond to the consolidation request. 

Lawsuits Alleging Infant Formula Caused NEC in Premature Babies

Enfamil and Similac are infant formulas made from cow’s milk that are fed to newborn babies instead of human breast milk.

An overwhelming body of scientific research and clinical studies have established that feeding cow-milk-based formulas like Similac and Enfamil to premature infants can dangerously increase the baby’s risk of developing necrotizing enterocolitis (NEC).

NEC is an extremely perilous bacterial infection that can occur in the intestinal tissue of a newborn. NEC causes tissue in the baby’s intestinal walls to decay and die. This can cause holes in the intestines to form and allow aggressive bacteria to invade the baby’s abdominal cavity. This can eventually lead to a systemic bloodstream infection called sepsis, which is often fatal. Somewhere between 10-28% of premature babies with NEC die from sepsis or other complications.

The research showing that cow-milk formulas like Similac and Enfamil increase the risk of NEC in premature babies has been around for decades. The manufacturers of these formulas have known about this but chose not to include any warning language or guidelines about the risk of NEC associated with their products. Similac is made by Abbott Laboratories Inc. (“Abbott”) and Enfamil is manufactured by Mead Johnson Nutrition  (“Mead”).

nec lawsuits

Over the last 12 months, a stream of product liability lawsuits has been brought against Abbott and Mead regarding their failure to warn about the risk their products present for NEC in premature infants. The lawsuits are being filed by parents on behalf of premature babies who were fed Similac or Enfamil and subsequently developed an NEC infection resulting in serious injury or death. The allegations in these lawsuits are simple and powerful. The plaintiffs claim that if Mead and Abbott had included a warning NEC and preemies on their products, they would have used a different formula and their children would not have developed NEC.

NEC Formula Lawsuits Currently Pending

So far it looks like 7 infant formula NEC lawsuits have appeared in the federal courts against Abbott and/or Mead Johnson. Below is a list of the NEC lawsuits in the federal court system as of October 2021:

5/14/2021 Restad v. Abbott Laboratories California (Eastern Dist.)
5/11/2021 Jupiter v. Mead Johnson & Company Illinois (Southern Dist.)
3/18/2021 Sanchez v. Abbott Laboratories Florida (Middle Dist.)
3/18/2021 Patriece v. Abbott Laboratories California (Central Dist.)
3/12/2021 Gschwend v. Abbott Laboratories Tennessee (Western Dist.)
2/25/2021 Rinehart v. Abbott Laboratories Georgia (Northern Dist.)
1/21/2021 Ferry v. Mead Johnson & Company Connecticut

All 5 of these cases were originally filed in state courts and removed to federal court on the basis of diversity jurisdiction. The Jupiter case in the Southern District of Illinois was eventually remanded back down to state court in Madison County, Illinois, because diversity jurisdiction did not apply because Illinois is the home state of both Abbott and Mead. Not all these cases are still “pending.” 2 of the cases listed above have been voluntarily dismissed, possibly because of a settlement.

The cases listed above do include Similac or Enfamil NEC lawsuits that are pending in Illinois state courts and were not subject to removal based on diversity, or those filed in other states which the defendants opted not to remove. Although the number of NEC formula lawsuits filed so far is small, the volume of new NEC lawsuit filings is expected to grow rapidly over the next year are more potential plaintiffs become aware of the litigation.

NEC Baby Formula Litigation Defense Team and Strategy

Abbott’s defense team for the formula NEC lawsuits is made up of lawyers from the Chicago office of Winston & Strawn LLC along with local counsel. Winston & Strawn is a large national firm that frequently defends Abbott in other product liability cases involving medical devices. The same Winston & Strawn lawyers are named as defense counsel for Abbott in all of the NEC lawsuits.

Mead Johnson’s defense lawyers in the NEC lawsuits are more of a mixed bag. In some of the cases, Mead’s primary national defense counsel appears to be headed by lawyers from the Chicago office of Steptoe & Johnson, LLP, another national law firm that often defends product cases. But in some of the cases, Mead is defended by yet another national law firm, Baker Donelson.

The defense strategy for Abbott and Mead in the NEC lawsuits so far is somewhat varied. In some cases, such as the Ferry case filed in Connecticut, Abbott and Mead have adopted a highly aggressive strategy and responded to the complaint with a motion to dismiss right out of the gate. In other cases, however, the defense seems content to file a general answer denying the allegations and then just sit back and wait.

Will the Infant Formula NEC Lawsuits be Consolidated in a New MDL?

Right now there simply are not enough NEC formula lawsuits out there to trigger any discussion of consolidation into a new MDL. However, interest in NEC lawsuits against the makers of Similac and Enfamil has really started to pick up and there is reason to anticipate that the number of NEC lawsuits will increase rapidly over the next year. If that happens, we could very well see a new MDL consolidation of the NEC lawsuits, with the Southern District of Illinois being the most likely venue.